Serratiopeptidase is an anti inflammatory enzyme commonly used in the treatment of various inflammatory disorders. It is found to have no GI related side effects unlike NSAIDs and can be safely used for chronic conditions. Formulations of controlled release tablets can decrease the frequency of administration and thereby improve the patient compliance. As Serratiopeptidase is acid-liable, it is made into enteric dispersion with the polymer viz. Eudragit L 100 by solvent evaporation technique. The polymer is used in various proportions and the optimum solid dispersion was selected based on the drug release study for enteric products. The controlled release tablets of the Serratiopeptidase solid dispersion were prepared with the polymers viz. ethyl cellulose, hydroxypropylmethylcellulose and methylcellulose in various proportions. Drug release study was conducted for 6 hours in pH 6.8 phosphate buffer. The formulation containing ethyl cellulose in 125 mg quantity showed drug release in controlled manner upto 6 hours. Key words: Enteric dispersion, Serratiopeptidase, Eudragit L100, Controlled Release Tablets.
Serratiopeptidase is an anti-inflammatory enzyme derived from the non-pathogenic enterobacteria Serratia marcescences strain E15. It is a systemic enzyme which is highly specific for its substrate without eliciting any side effects. It is devoid of unpleasant actions created by inhibition of the COX-1 enzymes unlike NSAIDs. Moreover it has an antioedemic and fibrinolytic action which makes it useful in sciatic pain, sinusitis, pneumonia, skin rash, tonsillitis, atherosclerotic pain and post child birth complications. Various marketed products of Serratiopeptidase belong to the class of immediate release and need intake of drug for thrice a day. In the present work an attempt was made to formulate controlled release tablets of Serratiopeptidase in order to decrease the frequency of administration.
Initially enteric dispersion of Serratiopeptidase with Eudragit L 100 was prepared by solvent evaporation technique. The selected solvent can dissolve the enteric polymer whereas serratiopeptidse is insoluble in it. This facilitates fine dispersion between the drug and the polymer. The enteric dispersion was optimized based on the assay and the drug release study for enteric products. Then controlled release formulations were designed to contain the enteric dispersion of Serratiopeptidase and drug release retarding polymers namely ethyl cellulose, hydroxypropylmethylcellulose and methyl cellulose in different concentrations.
Material and Methods
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Serratiopeptidase (J.C. Biotech Pvt Ltd., ongole), Eudragit L 100, Ethyl cellulose, Hydroxypropyl methylcellulose and Methyl cellulose are the ingredients used in the present work. All other materials used were of analytical grade.
Preparation of enteric dispersion
Drug and enteric polymer -Eudragit L 100 were taken in different proportions viz, 1:01, 1:0.2, 1:0.3, 1:0.4 and 1:0.5. Initially polymer was dissolved in ethanol taken in a round bottomed flask and then specific quantity of Serratiopeptidase was added to it and mixed well. This mixture was subjected to evaporation at 41 degree centigrade using rotary evaporator until a dry powder was obtained. The solid dispersion was collected from the round bottomed flask, pulverised and stored under appropriate conditions in a dessicator.
Evaluation of enteric dispersion
2.2.1Assay
Each solid dispersion was tested for the drug content. Definite quantity of solid dispersion equivalent to 10mg of solid dispersion was weighed and dissolved in 10ml of methanol. Dilute the solution suitably with pH 6.8 phosphate buffer and record the absorbance using UV spectrophotometer.
Dissolution study
100 mg of solid dispersion of different ratios was compressed into tablets. Dissolution study was conducted for 2 hours in 0.1N HCl and then in pH 6.8 phosphate buffer for one hour. 5ml samples were withdrawn at regular intervals of 30minutes and samples are analyzed spectrophotometrically.
Preparation of Controlled release tablets
Formulations consisting of solid dispersion equivalent to 30mg of Serratiopeptidase were prepared with release retarding polymers namely ethyl cellulose, hydroxypropylmethylcellulose, methyl cellulose in different concentrations. Wet granulation followed by lubrication and compression of tablets was done using rotary tablet punching machine. dispersion  43  43  43  43  43  43  43  43  43  2  Ethyl cellulose  75  100  125  ------3  Hydroxypropylmethylcellu  lose   ---75  100  125  ---4  Methyl cellulose  ------75  100  125  5  Microcrystalline cellulose  80  55  30  80  55  30  80  55  30  6  Magnesium stearate  3  3  3  3  3  3  3  3  3  7  Total  200  200  200  200  200  200  200  200  200 
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The prepared tablets were evaluated for weight uniformity, hardness, friability and drug content.
2.4.1Dissolution study
Dissolution study was conducted for 2 hours in 0.1N HCl and then in pH 6.8 phosphate buffer for 6 hours. 5ml samples were withdrawn at regular intervals of 30minutes and samples are analyzed spectrophotometrically. Out of the different enteric dispersions, the dispersion containing drug: polymer in 1:0.4 ratio was found to have more drug content while the dispersion with 1:0.3 has the least drug content. With the increase in polymer proportion, it was found that the drug release from enteric dispersion into 0.1N HCl was found to be decreased which can be attributed to the increase in entrapped quantity of drug in the polymer matrix and thereby decreased drug release from the enteric dispersion. at the end of 2 hours enteric dispersion with the drug-polymer ratio of 1:0.4 showed a drug release of 19.25% while other dispersions had a drug release of more than 25% within 2 hours. Based on this it was selected as the optimum enteric dispersion for formulation into controlled release tablets.
Results and Discussion
3.1.2Drug release data of enteric dispersion
Evaluation of controlled release tablets
All the tablets were found to have percentage weight variation, hardness, % friability and percentage drug content within the pharmacoepial limits. Table 4 : Drug release study data of controlled release tablets Among the nine formulations prepared, SEC3 was found to show drug release of 72.31% in 6 hours while the other formulations had drug release greater than that formulation which may be attributed to the hydrophobic nature of ethylcellulose unlike the two other polymers used. The regression coefficients of zero order were found to be nearer to 1. So the drug release from the tablets follows zero order kinetics. The value for Higuchi's mechanism were found to be far away from 1 and the Peppa's n values are in the range of 0.795-1.195 indicating the drug release following anamolous diffusion mechanism but not Higuchi's mechanism.
3.2.1Drug release study of controlled release tablets
S.No
Conclusion:
Based on the results it can be concluded that the prepared enteric dispersion with the drug:polymer ratio of 1:0.4 was found to have enteric character and the tablets prepared with that dispersion using ethyl cellulose in 62.5%w/w exhibited drug release in controlled manner upto 6 hours as confirmed by regression coefficient values for zero order and peppas mechanism. 
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